TBCRC071 PREDICT-RD
What is the Purpose of this Study?
This study may last about three years. Participants will have a screening visit, blood tests, surveys about their health and well being, physical exams, and reviews of their medical records. Blood samples will be collected about every six weeks during standard cancer treatment to look for small signs of cancer in the blood, called circulating tumor DNA. Follow up visits will happen about every twelve weeks.
If no circulating tumor DNA is found, participants will continue with their regular monitoring and follow up care. If circulating tumor DNA is found, participants may be offered a study medicine called datopotamab deruxtecan. This medicine is given through a vein every three weeks. Participants who receive this treatment will continue having blood tests so researchers can monitor their cancer and how well the treatment is working.
Early-stage triple-negative breast cancer (TNBC) in participants who still have cancer remaining after surgery (residual disease)
Who Can Participate in the Study?
People can join this study if they are adults with an early stage type of breast cancer called triple negative breast cancer. After surgery, they must still have some cancer cells remaining. They must be receiving or planning to receive standard treatment after surgery. Participants must be willing to provide blood samples, attend study visits, and complete surveys. The study will use this information to learn more about cancer and how to improve treatment and follow up care.
What is Involved?
This study is testing whether a blood test called circulating tumor DNA (ctDNA) can help find signs that triple-negative breast cancer may return after treatment.